Phase 2 Single Arm Trial Testing the ZN-c3 WEE1 Inhibitor in Combination With Gemcitabine in Second-Line Advanced Pancreatic Adenocarcinoma
The Phase 2 trial of ZN-c3, a WEE1 inhibitor, in combination with gemcitabine for second-line treatment of advanced pancreatic adenocarcinoma addresses a significant unmet need in a challenging oncology market. Given the high mortality rate associated with pancreatic cancer and limited effective treatments, successful outcomes could position ZN-c3 as a valuable addition to the therapeutic arsenal. The involvement of notable collaborators, including the Lustgarten Foundation and Zentalis Pharmaceuticals, enhances credibility and potential funding avenues. However, the competitive landscape includes established therapies and emerging agents targeting similar pathways, necessitating a robust differentiation strategy. The trial's outcomes may influence future licensing or partnership opportunities, particularly if the combination demonstrates superior efficacy or safety profiles compared to existing treatments.
Indication: Advanced Pancreatic Adenocarcinoma
Modality: small molecule
Target: WEE1 tyrosine kinase
Sponsor: Brandon Huffman, MD
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: WEE1 tyrosine kinase
View original source fields
Condition raw: Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Condition normalized: Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: WEE1 tyrosine kinase
Target normalized: WEE1 tyrosine kinase